All In Biotech

Drug Trial Radar · NCT05935358

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Nov 28, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
OctapharmaIndustry
Sponsor type
Industry
First posted
Jul 7, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis

Conditions

  • Severe Hemophilia A

Interventions

  • NuwiqDrug

    Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall haemostatic efficacyTime frame: During surgery and until completion of wound healing (e.g. removal of sutures, cessation of drainage, etc.) as defined by the investigator, during the study duration of 30 ± 3 days after the day of surgical procedure

Locations

18 sites in 11 countries. Site status is shown where the registry gives one.

  • UT Southwestern Medical Center

    Dallas, Texas · Recruiting

  • University Hospital Centre Zagreb

    Zagreb, Croatia · Recruiting

  • Helsinki University Hospital

    Helsinki, Finland · Recruiting

  • CHU de Nantes Hôtel-Dieu

    Nantes, France · Recruiting

  • CHRU de Tours

    Tours, France · Terminated

  • Vivantes Klinikum im Friedrichshein (KFH)

    Berlin, Germany · Terminated

  • Gerinnungszentrum Rhein-Ruhr

    Duisburg, Germany · Recruiting

  • Universitätsklinikum Hamburg Eppendorf (UKE)

    Hamburg, Germany · Recruiting

  • St. John's Medical College Hospital

    Bengaluru, India · Recruiting

  • Christian Medical College Vellore

    Vellore, Tamil Nadu, India · Completed

  • Azienda Ospedaliera Pugliese Ciaccio

    Catanzaro, Italy · Terminated

  • Azienda Ospedaliero Universitaria Careggi - Centro Emofilia

    Florence, Italy · Terminated

  • Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital

    Milan, Italy · Terminated

  • Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia

    Skopje, North Macedonia · Recruiting

  • Clinical Center for Serbia Belgrade

    Belgrade, Serbia · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Terminated

  • St. James's University Hospital

    Leeds, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.